# Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

> **NCT03364153** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 121 (actual)

## Conditions studied

- Stargardt's Macular Dystrophy

## Interventions

- **DRUG:** avacincaptad pegol
- **DRUG:** Sham

## Key facts

- **NCT ID:** NCT03364153
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-12
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03364153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03364153, "Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03364153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*